This prospective study evaluated the prognostic value of antibodies to carcinoembryonic antigen (anti-CEA), detected by indirect immunosorbent assay, in the serum of colorectal carcinoma patients. Serum carcinoembryonic antigen (CEA) concentrations, measured by electrochemiluminescence immunoassay, were elevated in 26 (37.7%) of 69 patients with colorectal cancer and could not be detected among the 28 patients with benign intestinal conditions or 37 healthy individuals who comprised the control groups. Anti-CEA immunoglobulin (Ig)G or IgM was detected by immunonephelometry in 44 (63.8%) patients with colorectal cancer, three (10.7%) with benign intestinal conditions and four (10.8%) healthy blood donors. Differences in antibody detection frequencies between the cancer patient group and the control groups were statistically significant. Titres of anti-CEA correlated significantly with CEA levels and Dukes' cancer stage. Antibody titre was an independent, significant, favourable predictor for 5-year recurrence-free survival. It is concluded that measurement of serum anti-CEA combined with CEA might be useful as a tumour marker and to assess prognosis. These results need to be confirmed in large, well-controlled, randomized clinical trials.
Introduction
Carcinoembryonic antigen (CEA) was first identified in 1965 by Gold and Freedman 1 from colon and pancreatic cancer tissues. It is a 180 kDa glycoprotein with a 21 kb complementary DNA. 2, 3 CEA is highly expressed in many types of human epithelial tissues, endoblast tissues and pathogens that affect these tissues, and might be involved in tumour cell immune *X-J Wu and Y-J Fang contributed equally to this article as lead authors. X-J Wu, Y-J Fang, J-Z Lin et al. Anti-CEA and survival in colorectal cancer escape and migration. 1 -4 Since it is also known to be highly expressed in a large proportion (60 -90%) of patients with colorectal cancer, it may be an effective biomarker in helping to evaluate prognosis, and to monitor therapeutic effects and cancer migration or recurrence. 5, 6 Although many studies have focused on studying CEA in blood and its role in the cellular immunity of colorectal cancer, its prognostic value in cancer patients still remains controversial. 7 -12 The aim of this study was to measure concentrations of antibodies to CEA (anti-CEA) in serum and tumour tissue, and to determine the prevalence and prognostic value of serum levels of anti-CEA as a biomarker in colorectal cancer.
Patients and methods

STUDY PARTICIPANTS
Colorectal cancer patients attending the Cancer Centre at Sun Yat-sen University, Guangzhou, China, in 2002 were randomly selected for inclusion in this study. Only patients for whom this was their first diagnosis of colorectal cancer, who had no treatment-related disorders or diseases of the immune system and a complete clinical history were eligible to take part. None of the patients had undergone any previous treatment for colorectal cancer. Tumour location, size, gross appearance, histopathological type, pathological grade (according to the American Joint Committee on Cancer [AJCC] staging system) and Dukes' stage of colorectal cancer were recorded. Healthy individuals and patients with benign intestinal tract disease were randomly selected as controls; healthy individuals were sourced from government records of routine annual health assessments and patients with benign intestinal tract disease were selected from those attending the Cancer Centre at Sun Yat-sen University.
The study was approved by the Medical Ethics Committee of the Cancer Centre at Sun Yat-sen University, Guangzhou, China and all patients and controls provided written informed consent to participate in the study.
SAMPLE COLLECTION AND ANALYSIS
Blood samples were collected from all participants between 08.00 h and 10.00 h, after a 12 h fast and stored at -80°C until analysis. Tumour tissue was routinely taken during operation.
Serum concentrations of CEA were measured by electrochemiluminescence immunoassay of monoclonal antibodies, using the commercially available E170 modular immunoassay analyser (Roche Diagnostics, Mannheim, Germany), with the manufacturer's recommended cut-off limit of 5 ng/ml. Concentrations of CEA in tumour tissue obtained routinely during operation, were measured by immunohisto chemistry.
After determining the correct dilution and optimizing the working concentration of enzyme-labelled antibody, indirect enzymelinked immunoassay was used to measure circulating anti-CEA immunoglobulin (Ig)G and IgM levels in serum. 13 For each patient, 96-well microplates were coated with 100 µl of 0.5 mg/100 ml CEA antigen and incubated overnight at 4°C. The plates were washed and incubated for 1 h at 37°C with 100 µl/well of a 1% phosphate buffered saline and bovine serum albumin (PBS-BSA) solution, pH 7.2, to prevent non-specific binding. After washing the plates with Tween 0.5% solution the serum of the patients was added (1:100 dilution) and the plates were incubated at 37°C for 1 h. After washing the plates a second time, 100 µl peroxidase-labelled antihuman IgG and IgM (dilution 1:5000; Sigma-Aldrich, St Louis, X-J Wu, Y-J Fang, J-Z Lin et al. Anti-CEA and survival in colorectal cancer MO, USA) was added and the samples were incubated for a further 1 h at 37°C.
Conjugated IgG and IgM anti-CEA were detected with the peroxidase method, with ophenylenediamine dihydrochloride as the substrate. The reaction was terminated with concentrated hydrochloric acid (0.1 mol/l). Immunonephelometry was used to assess enzymatic activity by measurement of the optical density at 492 nm.
Specificity of the anti-CEA was determined by competitive inhibition assay, in which 50 µl serum (1:50 dilution) and a series of anti-CEA standards (0 -80 µg/ml) at 50 µl each were incubated at 37°C for 1 h. Samples were added to microplates coated with CEA (5 µg/ml) and processed according to the steps described above.
A 3% PBS-BSA solution was used as negative control. Purified (> 98%) CEA antigen from serum and mouse anti-CEA IgG (Sigma-Aldrich) were used as positive controls. Concentrations of CEA higher than the cut-off value of 5 ng/ml and optical densities greater than the upper limit of the 95% CI anti-CEA level of healthy subjects were taken to be positive results.
FOLLOW-UP
Follow-up information on the cancer patients was obtained from the Medical Registry of the Cancer Centre at Sun Yat-sen University.
STATISTICAL ANALYSES
Statistical analyses were performed with SPSS ® software, version 13.0 (SPSS Inc., Chicago, IL, USA). The χ 2 -test was used to compare between the patient and control groups. Univariate analysis of survival was conducted with Kaplan-Meier survival curves and results were compared with the log-rank test. Significant (P ≤ 0.05) factors from the univariate analysis were entered into a multivariate Cox proportional hazards models to assess prognostic value. Values of P ≤ 0.05 were taken to be statistically significant. 
Results
STUDY PARTICIPANTS
SERUM AND TISSUE CEA AND ANTI-CEA LEVELS
Results for CEA and/or anti-CEA IgG or IgM testing are shown in Table 2 . The number of colorectal cancer patients who were positive for CEA or anti-CEA in serum (58/69 [84.1%] patients) was significantly higher than the number of patients who were positive for anti-CEA or CEA alone (P < 0.01); 12/69 (17.4%) patients had both CEA and anti-CEA Results from the competitive inhibition assay (decrease in optical density at 492 nm) showed that 30% of serum was completely inhibited and about 50% was partially inhibited by 80 µg/ml CEA. A significant inverse relationship was observed between serum CEA and anti-CEA: positivity for anti-CEA was significantly higher among participants who were negative for serum CEA (P < 0.01). Anti-CEA was detected in the serum of 32 of the 43 patients (74.4%) who were CEA negative (< 5 ng/ml), 32 of 41 patients (78.0%) with normal serum CEA levels and positive levels of tissue CEA and in only 12 of 26 patients (46.2%) with high serum CEA concentrations. Only two out of 69 (2.9%) colorectal cancer cases were negative for tumour tissue CEA. The presence of serum anti-CEA was not significantly associated with CEA in tumour tissue, gross specimen characteristics, tumour location, tumour size, histopathology or pathological stage.
FOLLOW UP AND SURVIVAL
Follow-up data were available for 67 (97.1%) of the colorectal cancer patients. The latest follow-up date was October 2008 and the median duration of follow-up was 73 months (range 9 -93 months). Positivity for anti-CEA was associated with an increased 5year recurrence-free survival: patients positive for both IgG and IgM antibodies had the longest recurrence-free survival, followed by positivity for IgM alone, IgG alone and no antibody ( Fig. 1 ). Univariate analysis showed that the Dukes' stage was related to prognosis and multivariate analysis based on Dukes' stage revealed that anti-CEA titre was the only independent prognostic factor for recurrence-free survival.
Discussion
Under physiological conditions, the digestive tract mucosa secretes small amounts of CEA into the intestinal lumen and concentrations in blood are very low (2 µg/l). In normal cells, CEA helps to establish polarity of the cell membrane surface. 2, 3, 14 In the process of cell carcinogenesis, tissues overexpress CEA and promote heterotypic cell changes that 
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lead to localization of CEA in the cytoplasm and membrane and loose polarity, resulting in increased secretion of CEA into blood. 2, 3, 5, 14, 15 Concentrations of CEA also Comparison between the colorectal cancer patients and control groups in terms of positivity for serum carcinoembryonic antigen (CEA) and immunoglobulin (Ig)M and IgG antibodies to CEA (anti-CEA) Anti-CEA and survival in colorectal cancer increase in other body fluids, such as pleural effusion, ascitic fluid, gastric fluid, bronchial fluid, bile and urine. 2,3,5 -7,14,15 The detection of high concentrations of CEA in blood is, therefore, is thought to be a useful indicator of the existence of a gastrointestinal tumour. 5 -8,14,15 After removal of colonic tumours, Lokich et al. 16 suggested that CEA clearance occurs in two phases: an immediate decline of 63 -89% in concentrations of circulating CEA in plasma, followed by a logarithmic decline in concentrations with incremental extensions in concentration half-life. The first stage probably reflects a dynamic equilibrium between tumour secretion and plasma concentrations. The second-phase kinetics are variable, which might be related to the circulating concentration of CEA or to pathophysiological processes influencing CEA metabolism or secretion in the liver.
According to the current American Society of Clinical Oncology guidelines on biomarkers for gastrointestinal tumours, 17 detection of raised CEA concentrations in serum is not suitable for the early diagnosis of colorectal cancer. By contrast, the American Joint Committee on Cancer 18 recognizes measurement of CEA levels as a useful part of routine postoperative monitoring of therapeutic response and recurrence or metastases and, on the basis of research showing that raised CEA concentrations in blood constitute a negative prognostic factor independent of tumour, node, metastases (TNM) staging, has suggested classifying the preoperative CEA concentration in serum as a type I prognostic factor. They propose modification of the TNM staging for colorectal cancers to I -IV C x C 0 C 1 . 18 An issue with the use of CEA as a prognostic factor is that fewer than half of patients with colorectal cancer, even at the advanced stages, have increased serum CEA values. 18, 19 In accordance with this finding, in the present study only 43.3% of patients had CEA concentrations higher than the cutoff value (5 ng/ml). Various reasons have been put forward for this outcome: different laboratories might have different cut-off values for positivity; not all tumour types secrete CEA; 19, 20 tumours might secrete CEA but only a small amount or none enters the bloodstream 18, 19, 21 or the systemic immune response produces antibodies to CEA and specific binding leads to formation of an easily excreted complex. 8, 13, 16, 21 The present study showed significant differences in serum positivity for anti-CEA between patients with colorectal cancer compared with the control groups. The combination of serum positivity for anti-CEA and detection of serum CEA included even more colorectal cancer patients. Anti-CEA was detected among many study participants who did not have raised serum concentrations of CEA. In addition, colorectal cancer who had normal serum CEA levels and raised tissue concentrations of CEA showed a higher rate of positivity for anti-CEA than patients with raised serum concentrations of CEA alone. We suggest that the low serum level of CEA may have been due to a lack of release of CEA from the tumour into the circulation and the immune response might have been triggered by immune cells coming into direct contact with non-circulating antigens on the surface of the tumour cells. Positivity for anti-CEA is related to immune function and patients with good immune function produce more antibody and form high affinity antigenantibody complexes that are excreted, resulting in raised titres of anti-CEA antibodies without increased blood concentrations of CEA. 8,13,16,22 -25 The positive correlation between serum anti-CEA 25 Among patients with early-stage colorectal cancer (Dukes' stages A and B) a notable proportion had detectable titres of anti-CEA, which is consistent with results reported elsewhere. 23 -25 In the present study, no relationship was seen between anti-CEA titres and prognosis, but a correlation between anti-CEA levels in serum and increased likelihood of 5-year recurrence-free survival was found, confirming previous reports. 24, 25 In summary, most patients with colorectal cancer had detectable titres of circulating anti-CEA, which correlated strongly with 5year recurrence-free survival and, therefore, might complement measurement of CEA concentrations in serum in assessment of prognosis. Further studies are needed with a larger sample size and to determine the mechanism of the relationship between anti-CEA, colorectal cancer and immune function.
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